+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pegcetacoplan Injection Market by Indication (Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria), Strength (1080 Mg, 180 Mg), End User, Distribution Channel, Payment Type - Global Forecast 2025-2030- Product Image
Pegcetacoplan Injection Market by Indication (Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria), Strength (1080 Mg, 180 Mg), End User, Distribution Channel, Payment Type - Global Forecast 2025-2030- Product Image
New

Pegcetacoplan Injection Market by Indication (Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria), Strength (1080 Mg, 180 Mg), End User, Distribution Channel, Payment Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118256
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Pegcetacoplan Injection has rapidly emerged as a pioneering therapeutic in the complement inhibition landscape, offering clinicians a novel mechanism of action that directly targets the C3 protein to modulate downstream inflammatory processes. With its biweekly subcutaneous dosing regimen, the therapy addresses critical unmet needs across rare hematological disorders and progressive retinal diseases, delivering improved functional outcomes and quality of life for patients who previously relied on more invasive or less specific interventions.

The advent of Pegcetacoplan reflects a broader evolution in translational science, where precision immunomodulation replaces broad-spectrum approaches. Early clinical trials demonstrated robust efficacy in reducing hemolysis markers among patients with paroxysmal nocturnal hemoglobinuria and slowed geographic atrophy progression in imaging studies. As real-world evidence begins to accumulate, prescribers and payers alike recognize the value proposition of a therapy that simultaneously addresses systemic and ocular complement-mediated pathologies.

Against this backdrop, the commercial narrative is shifting from monolithic delivery paradigms to holistic patient engagement models. Stakeholders are adapting to home-based administration protocols supported by digital adherence platforms, while regulatory agencies continue to refine frameworks that expedite access for breakthrough therapies. This report sets the stage for a deep dive into the forces reshaping adoption and commercialization of Pegcetacoplan Injection, offering a granular perspective on clinical innovation, market dynamics, and strategic imperatives.

Charting the Paradigm Shift Shaping Complement Inhibitor Strategies with Innovative Administration Models and Emerging Patient Engagement Technologies

The competitive landscape for complement inhibitors is experiencing seismic shifts driven by advances in molecular engineering, patient empowerment, and digital connectivity. Pharmaceutical developers are reimagining administration formats to reduce treatment burden, with a clear pivot toward subcutaneous delivery and at-home infusion models that align with evolving patient preferences and public health imperatives.

In parallel, digital therapeutics and remote monitoring platforms are gaining traction, enabling seamless tracking of adherence, adverse events, and quality-of-life measures. These insights feed into adaptive clinical trial designs, accelerating go-to-market strategies and enhancing post-launch pharmacovigilance. On the regulatory front, agencies are increasingly receptive to real-world evidence packages and surrogate endpoints, streamlining approvals for indications that demonstrate meaningful improvement over standard of care.

Furthermore, strategic alliances between biotech innovators and specialty pharmacy networks are redefining distribution channels. Collaborative co-development agreements facilitate shared risk and investment in early-stage assets, while integrated patient support services strengthen engagement across the continuum of care. As biosimilar competition looms, brand differentiation hinges on value-based contracting, outcomes-driven rebates, and expansive patient assistance programs that underscore long-term therapeutic adherence.

Examining the Cumulative Impact of 2025 United States Tariff Adjustments on Advanced Complement Therapy Supply Chain Dynamics and Cost Structures

Looking toward 2025, adjustments to United States tariff schedules on key active pharmaceutical ingredients and specialty packaging components are poised to influence the economics of advanced injectables. Import duties on raw materials sourced from major manufacturing hubs may incrementally inflate production expenses, prompting manufacturers to revisit supply chain footprints and negotiate long-term procurement contracts.

These tariff shifts carry downstream implications for contracting with specialty distributors and payers. Reference pricing models and rebate structures must accommodate elevated cost inputs, while reimbursement negotiations will hinge on demonstrable clinical and economic value. Manufacturers are exploring nearshoring initiatives and dual-sourcing strategies to mitigate risk and maintain pricing stability in the face of potential trade policy volatility.

In addition, distribution margins across hospital pharmacy, retail pharmacy, and online fulfillment channels may adjust to reflect altered landed costs. Stakeholders are advised to conduct scenario analyses that quantify margin erosion and explore co-investment models to safeguard patient access. Ultimately, the ability to absorb or offset incremental tariff-driven expenses will become a critical differentiator for market entrants and incumbents alike.

Uncovering a Layered Perspective through Indication, Dose Strength, End User, Distribution Channel, and Payment Type Segmentation for Precision Market Understanding

The market for Pegcetacoplan Injection can be dissected through multiple segmentation lenses to reveal nuanced growth drivers and adoption patterns. When viewed by indication, the therapy’s dual efficacy profiles in geographic atrophy and paroxysmal nocturnal hemoglobinuria delineate distinct stakeholder imperatives-retinal specialists prioritize functional vision stabilization while hematologists emphasize hemolytic control and transfusion independence.

Dose strength segmentation further informs inventory management and dosing schedules, as the 180 mg formulation often serves as an initiation dose in acute settings, whereas the 1080 mg option is tailored for maintenance therapy and long-term disease modulation. Insights into end-user dynamics highlight divergent service delivery requirements: home healthcare providers focus on patient training and remote support infrastructure, hospitals integrate infusion suites and multidisciplinary oversight, and specialty clinics emphasize streamlined referrals and reimbursement navigation.

From the perspective of distribution channels, hospital pharmacies must balance stocking efficiency with emergent demand, online pharmacies leverage digital fulfillment networks to expedite delivery, and retail pharmacies play a pivotal role in bridging community-based access and adherence initiatives. Payment type segmentation underscores the criticality of government reimbursement frameworks, the variability of out-of-pocket cost burdens on patients, and the negotiating power of private insurance payers-all of which shape go-to-market strategies and contracting priorities.

Dissecting Regional Variations across the Americas, EMEA, and Asia-Pacific Highlights to Optimize Market Access and Commercial Deployment Strategies

Regionally, the Americas region presents a mature reimbursement environment with established pathways for rare disease therapies and growing investment in home infusion networks. Market entrants benefit from comprehensive data registries and a payer ecosystem that increasingly favors value-based arrangements to manage long-term treatment costs in both hematology and ophthalmology applications.

In contrast, Europe, Middle East & Africa terrain offers a complex mosaic of national health systems, each with unique regulatory affordances and pricing authorities. While some markets accelerate access through early-access programs and joint clinical pathways, others impose stringent pharmaco-economic assessments that necessitate robust health economic evidence generation to secure formulary placement.

Across Asia-Pacific, diverse healthcare infrastructure and evolving reimbursement schemes create both challenges and opportunities. Key markets such as Japan and Australia demonstrate growing receptivity to innovative biologics, whereas emerging economies prioritize affordability and may impose tiered pricing structures. Partnerships with regional distributors and local clinical research centers are essential to navigate regulatory approvals and optimize national reimbursement negotiations.

Profiling Leading Innovators and Strategic Collaborators Driving Development, Partnerships, and Commercial Execution in the Pegcetacoplan Injection Arena

Leading players in the Pegcetacoplan Injection ecosystem are forging strategic alliances and expanding their portfolios to reinforce competitive advantage. The originator company has established a network of specialty pharmacy partnerships to streamline dispensing and patient education, while concurrently investing in co-promotion agreements to broaden geographic coverage.

Emerging biopharmaceutical firms are collaborating on clinical development programs to explore additional complement-mediated indications, from autoimmune conditions to neurodegenerative disorders. These partnerships often involve milestone-based licensing fees and profit-sharing arrangements that align incentives across development milestones and commercial performance targets.

Logistics and distribution specialists are enhancing cold-chain capabilities and digital tracking systems to ensure product integrity and minimize wastage. In parallel, contract research organizations and clinical trial service providers are scaling capabilities to support adaptive study designs and accelerated evidence generation. This constellation of alliances underpins a robust innovation ecosystem, driving continuous improvement in patient outcomes and operational efficiency.

Delivering Targeted Strategic Imperatives to Support Market Penetration, Stakeholder Alignment, and Sustainable Growth in Complement Inhibitor Therapy Deployment

Industry leaders seeking to maximize the commercial potential of Pegcetacoplan Injection should prioritize the development of integrated patient support services that extend beyond dosing instruction to include digital adherence monitoring, financial counseling, and telehealth follow-up. By embedding these offerings into reimbursement negotiations, manufacturers can differentiate their value proposition and reinforce payer partnerships.

It is equally important to diversify the supply base for key active pharmaceutical ingredients and packaging materials, implementing near-shoring initiatives where feasible to mitigate tariff exposure and strengthen business continuity. Negotiating multi-year contracts with tubular suppliers and leveraging collaborative forecasting will reduce lead times and buffer against market fluctuations.

To cultivate real-world evidence, stakeholders should establish registries and observational cohorts across diverse practice settings, capturing longitudinal data on safety, efficacy, and healthcare resource utilization. This evidence will support global reimbursement submissions and provide a compelling narrative for value-based contracting. Lastly, adopting a region-specific market access playbook-aligned with national HTA requirements and payer frameworks-will accelerate formulary acceptance and optimize early uptake across heterogeneous healthcare ecosystems.

Outlining the Rigorous Multi-Source Data Collection, Analytical Framework, and Validation Processes Underpinning Robust Market Insights and Decision Support

This analysis is grounded in a multi-tiered research approach that integrates primary interviews with key opinion leaders in hematology, ophthalmology, health economics, and managed care. These qualitative insights were triangulated with secondary research drawing on peer-reviewed literature, clinical trial registries, regulatory filings, company publications, and relevant government databases.

Quantitative inputs were refined through proprietary data models that harness historical prescription volume trends, distribution channel analytics, and reimbursement rate schedules. Rigorous validation procedures included cross-referencing public financial disclosures, on-the-record commentary from payer experts, and third-party logistics performance metrics.

Analytical frameworks such as SWOT analysis, Porter’s Five Forces, and scenario planning were employed to illuminate competitive intensity, bargaining power across the value chain, and potential market scenarios under varying trade policy environments. This robust methodology ensures that the insights presented herein are both actionable and defensible, empowering decision-makers to navigate an increasingly complex therapeutic landscape with confidence.

Synthesizing Key Insights to Illuminate the Future Trajectory of Pegcetacoplan Injection Adoption and Operational Excellence in Complement Inhibitor Therapy

In summary, Pegcetacoplan Injection represents a watershed advancement in complement inhibition, bridging critical gaps in the management of paroxysmal nocturnal hemoglobinuria and geographic atrophy. The therapy’s unique mechanism of action, combined with patient-friendly delivery formats, positions it at the forefront of next-generation biologics designed to transform care pathways.

As the 2025 tariff environment introduces new cost considerations, stakeholders must adopt proactive supply chain strategies and evidence-based contracting models to uphold favorable access and pricing outcomes. Segmentation insights underscore the importance of tailoring commercialization efforts to distinct clinical indications, dosing regimens, care settings, distribution channels, and payer structures. Moreover, regional nuances in regulatory and reimbursement regimes demand targeted market access approaches across the Americas, EMEA, and Asia-Pacific.

Collaborative innovation among originators, biotechnology partners, specialty pharmacies, and health systems will shape the competitive blueprint for Pegcetacoplan Injection in the years ahead. By leveraging integrated patient support, diversified sourcing, and robust real-world evidence, industry players can secure durable differentiation and deliver meaningful improvements in patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Indication
    • Geographic Atrophy
    • Paroxysmal Nocturnal Hemoglobinuria
  • Strength
    • 1080 Mg
    • 180 Mg
  • End User
    • Home Healthcare
    • Hospital
    • Specialty Clinic
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Payment Type
    • Government Reimbursement
    • Out Of Pocket
    • Private Insurance
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Apellis Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of updated clinical guidelines on pegcetacoplan injection adoption in AMD treatment
5.2. Cost reimbursement challenges affecting patient access to pegcetacoplan injection therapies
5.3. Emerging biosimilar competition shaping pricing strategies for pegcetacoplan injection market
5.4. Evolving payer policies influencing coverage decisions for pegcetacoplan injection in US Medicare
5.5. Advancements in intravitreal delivery technologies improving patient compliance with pegcetacoplan injections
5.6. Regional market expansion trends for pegcetacoplan injection uptake in Asia Pacific ophthalmology
5.7. Real-world evidence from postmarketing surveillance reinforcing clinical value proposition of pegcetacoplan injections
5.8. Strategic collaborations between pharma manufacturers and retina specialists driving pegcetacoplan adoption strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pegcetacoplan Injection Market, by Indication
8.1. Introduction
8.2. Geographic Atrophy
8.3. Paroxysmal Nocturnal Hemoglobinuria
9. Pegcetacoplan Injection Market, by Strength
9.1. Introduction
9.2. 1080 Mg
9.3. 180 Mg
10. Pegcetacoplan Injection Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospital
10.4. Specialty Clinic
11. Pegcetacoplan Injection Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Pegcetacoplan Injection Market, by Payment Type
12.1. Introduction
12.2. Government Reimbursement
12.3. Out Of Pocket
12.4. Private Insurance
13. Americas Pegcetacoplan Injection Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Pegcetacoplan Injection Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Pegcetacoplan Injection Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Apellis Pharmaceuticals, Inc.
16.3.2. Swedish Orphan Biovitrum AB
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PEGCETACOPLAN INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PEGCETACOPLAN INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PEGCETACOPLAN INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PEGCETACOPLAN INJECTION MARKET: RESEARCHAI
FIGURE 26. PEGCETACOPLAN INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 27. PEGCETACOPLAN INJECTION MARKET: RESEARCHCONTACTS
FIGURE 28. PEGCETACOPLAN INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEGCETACOPLAN INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY 1080 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY 1080 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY 180 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY 180 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY OUT OF POCKET, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY OUT OF POCKET, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 72. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 73. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. CANADA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 82. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 83. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 88. MEXICO PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 131. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 134. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 135. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 140. GERMANY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 141. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 144. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 145. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. FRANCE PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 164. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 165. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 170. ITALY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 171. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 174. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 175. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. SPAIN PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 214. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 215. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. DENMARK PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 234. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 235. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 240. QATAR PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 241. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. FINLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 271. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 274. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 275. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. EGYPT PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 284. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 285. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. TURKEY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 301. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 304. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 305. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 310. NORWAY PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 311. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 314. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 315. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. POLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 324. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 325. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 330. SWITZERLAND PEGCETACOPLAN INJECTION MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC PEGCETACOPLAN IN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pegcetacoplan Injection market report include:
  • Apellis Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB

Related Topics

Related Reports

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 80 Pages
  • Global
From
Complement 3 Glomerulopathy Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Complement 3 Glomerulopathy Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 105 Pages
  • Global
From
Complement Inhibitors Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Complement Inhibitors Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Drugs for PNH Market by Drug Class (Proximal Complement Inhibitors, Terminal Complement Inhibitors), Route of Administration (Intravenous, Subcutaneous), Distribution Channel, End User, Line of Therapy, Age Group - Global Forecast 2025-2030 - Product Image

Drugs for PNH Market by Drug Class (Proximal Complement Inhibitors, Terminal Complement Inhibitors), Route of Administration (Intravenous, Subcutaneous), Distribution Channel, End User, Line of Therapy, Age Group - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Geographic Atrophy Market Report and Forecast 2025-2034 - Product Image

Geographic Atrophy Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.